Keytruda Tops Adcetris in Head-to-Head Hodgkin’s Trial

(MedPage Today) — Pembrolizumab (Keytruda) significantly improved progression-free survival (PFS) over brentuximab vedotin (Adcetris) for Hodgkin’s lymphoma patients who failed on or were ineligible for transplant, findings from KEYNOTE-204 showed…
Read More

Leave a Reply

%d bloggers like this: